Autolus Therapeutics announces retirement of chief financial officer and succession plan
10 January 2022 - 11:01PM
Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage
biopharmaceutical company developing next-generation programmed T
cell therapies, announced that Andrew J. Oakley plans to retire
from his position as chief financial officer with effect from 31
March 2022 and will concentrate on non-executive director roles. He
currently serves on the Boards of Union Therapeutics A/S and
Novaremed AG. Andrew will remain a senior advisor to Autolus until
March 2023. Dr. Lucinda Crabtree, senior vice president of finance
at Autolus, will be appointed chief financial officer following his
retirement.
“I want to thank Andrew for his years of service
to Autolus as chief financial officer and for the impact he has had
on the Company and the patients we serve,” said Dr. Christian Itin,
chief executive officer of Autolus. “With the recent deal with
Blackstone Life Sciences he leaves Autolus in a strong financial
position as we shape the product profile and the commercial
strategy of obe-cel, and we are delighted that Dr. Lucinda
Crabtree, who has served in a number of roles within the
organization, will succeed him as chief financial officer. We wish
Andrew much happiness in the next chapter of his career.”
“It has been a privilege to serve as CFO of
Autolus since 2018 and to support the company to a pivotal stage
with its lead candidate, obe-cel," said Andrew Oakley, chief
financial officer of Autolus. “I have enjoyed working with Lucinda
for the past two years at Autolus, and I know I leave the company
in good hands, supported by a strong finance team, and wish the
company great success for the benefit of both patients and all
other stakeholders.”
Dr. Lucinda Crabtree joined Autolus in January
2020 and currently serves as SVP Finance. Her prior roles included
VP, Investor Relations and Corporate Communications and more
recently she was heading up Business Strategy and Planning, which
included oversight of the Financial Planning and Analytics
function. Lucinda oversaw Autolus’ public offerings of American
Depositary Shares in 2020 and 2021 and was a key contributor in
closing the Blackstone transaction in November 2021. Prior to her
time at Autolus, Lucinda’s broad experience includes roles on the
buy and the sell side, including as a senior investment analyst and
in specialist sales. In her roles she has had experience analyzing
and monitoring public and private healthcare companies and has also
served as a board observer for several private healthcare companies
during her buyside role. Firms she has worked at include Woodford
Investment Management, Panmure Gordon, Goldman Sachs, J.P. Morgan
(having originally joined Bear Stearns) and Jefferies. Lucinda has
also held roles at Grunenthal Group and AstraZeneca. Lucinda holds
a first-class Bachelor of Science degree in Physiology and
Pharmacology from University College London and a PhD in
Pharmacology from University College London.
About Autolus Therapeutics
plcAutolus is a clinical-stage biopharmaceutical company
developing next-generation, programmed T cell therapies for the
treatment of cancer. Using a broad suite of proprietary and modular
T cell programming technologies, the Company is engineering
precisely targeted, controlled and highly active T cell therapies
that are designed to better recognize cancer cells, break down
their defense mechanisms and eliminate these cells. Autolus has a
pipeline of product candidates in development for the treatment of
hematological malignancies and solid tumors. For more information,
please visit www.autolus.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the "safe harbor" provisions of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements are
statements that are not historical facts, and in some cases can be
identified by terms such as "may," "will," "could," "expects,"
"plans," "anticipates," and "believes." These statements include,
but are not limited to, statements regarding Autolus’ development
of the obe-cel program; the future clinical development, efficacy,
safety and therapeutic potential of its product candidates,
including progress, expectations as to the reporting of data,
conduct and timing and potential future clinical activity and
milestones; and expectations regarding the initiation, design and
reporting of data from clinical trials. Any forward-looking
statements are based on management's current views and assumptions
and involve risks and uncertainties that could cause actual
results, performance, or events to differ materially from those
expressed or implied in such statements. These risks and
uncertainties include, but are not limited to, the risks that
Autolus’ preclinical or clinical programs do not advance or result
in approved products on a timely or cost effective basis or at all;
the results of early clinical trials are not always being
predictive of future results; the cost, timing and results of
clinical trials; that many product candidates do not become
approved drugs on a timely or cost effective basis or at all; the
ability to enroll patients in clinical trials; possible safety and
efficacy concerns; and the impact of the ongoing COVID-19 pandemic
on Autolus’ business. For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause Autolus’ actual results to differ from those contained in the
forward-looking statements, see the section titled "Risk Factors"
in Autolus' Annual Report on Form 20-F filed with the Securities
and Exchange Commission on March 4, 2021, as well as discussions of
potential risks, uncertainties, and other important factors in
Autolus' subsequent filings with the Securities and Exchange
Commission. All information in this press release is as of the date
of the release, and Autolus undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new
information, future events, or otherwise, except as required by
law.
Contact:
Julia Wilson+44 (0) 7818
430877j.wilson@autolus.com
Susan A. NoonanS.A. Noonan
Communications+1-212-966-3650susan@sanoonan.com
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Autolus Therapeutics (NASDAQ:AUTL)
Historical Stock Chart
From Apr 2023 to Apr 2024